Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
THYROLAR-0.25 is an oral tablet containing a combination of thyroid hormones (levothyroxine and liothyronine) approved since 1969 for thyroid hormone replacement. The drug treats hypothyroidism by providing exogenous thyroid hormones to restore normal metabolic function. It works by supplementing deficient endogenous thyroid hormone production.
Product is in late-stage lifecycle with moderate competitive pressure (30%), indicating a mature brand team focused on retention and optimization rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on THYROLAR-0.25 offers limited job openings (0 linked positions) and represents a career opportunity in legacy product management rather than growth or innovation. This role is best suited for professionals seeking stability in mature product stewardship, regulatory compliance expertise, or transition planning experience.
Worked on THYROLAR-0.25 at AbbVie? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.